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Histone deacetylases (HDACs) are involved in the regulation of transcription and their inhibitors are a promising class of new
anticancer drugs. We have previously reported Boc(Ac)Lys-AMC, also termed MAL, as a ﬂuorescent substrate for HDACs. Now
we present a modiﬁcation of MAL called Z-MAL that is characterized by an increased rate of conversion by histone deacetylases
of classes I and II and the recently discovered sirtuins (histone deacetylases class III). MAL and Z-MAL are the ﬁrst nonra-
dioactive substrates for class III enzymes. The new substrate Z-MAL allows for shorter assay times in inhibitor screening and is
applicable to diverse sources of deacetylase activity even with completely diﬀerent catalytic mechanisms. Interestingly, MAL
shows some relative preference toward class II, indicating that subtype selectivity in small-molecule HDAC substrates might be
obtained.
 2003 Elsevier Science (USA). All rights reserved.
Keywords: Histone deacetylase; Sirtuins; MAL; Z-MALHistone deacetylases (HDACs)1 are enzymes involved
in the posttranslational modiﬁcations of histones [1] and
other proteins such as p53 [2]. They are divided into
three classes in humans [3]. Classes I and II, which one
could also call the classical HDACs, consist of zinc-de-
pendent amidohydrolases while class III, the so-called
sirtuins, depend on NADþ as a cofactor that takes up
the acetate to form O-acetyl-ADP-ribose [4]. HDACs
deacetylate side chains of lysine residues in histone and
nonhistone substrates which modiﬁes structural features
and hence biological activities of these proteins. In the
case of histones this usually leads to transcriptional re-
pression. Aberrant gene silencing by recruited HDAC
activity has been linked to the pathogenesis of malignant
diseases [5]. Inhibitors of histone deacetylases lead to
protein hyperacetylation via intrinsic acetyltransferase
activity. This in turn usually causes a relief of tran-* Corresponding author. Fax: +49-251-83-32144.
E-mail address: jungm@uni-muenster.de (M. Jung).
1 Abbreviations used: HDACs, histone deacetylases; DMSO,
dimethyl sulfoxide; TSA, trichostatin A.
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doi:10.1016/S0003-2697(03)00276-8scriptional repression which may also induce reversal of
the malignant phenotype [6], and several HDAC inhib-
itors are already in clinical trials for the treatment of
cancer [7]. While HDACs therefore are clearly a target
for drug design the link between sirtuin activity and
lifespan increase [8] makes it questionable whether the
same is true for class III. Nevertheless, potent new sir-
tuin inhibitors would be very interesting at least for
mechanistic studies. Therefore, assays for the measure-
ment of histone deacetylase activity are important tools
for the unraveling of the function of these important
regulators of key cellular processes and aid in the dis-
covery of new potential therapeutic agents.
Traditional in vitro assays monitor the release of
tritiated acetic acid from radiolabeled histones [9] or
histone peptide fragments [10,11] via extraction and
scintillation counting. A high-throughput version using
a biotinylated peptide and scintillation proximity is
available also [12]. We have introduced ﬂuorescent oc-
tapeptides [13] and a small lysine derivative termed
MAL [14] as nonisotopic substrates for HDACs. Espe-
cially the latter allows for a convenient nonradioactivereserved.
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method for the determination of its enzymatic conver-
sion that may be amenable to high-throughput screen-
ing, the so-called HDASH procedure [15]. One of the
drawbacks of our substrate MAL is a limited rate of
conversion by HeLa nuclear extract which is a standard
source of human HDAC activity [16]. Here, we report
an improved substrate with better acceptance by HeLa
deacetylase activity. We also present for the ﬁrst time a
nonpeptidic substrate for sirtuin (class III histone de-
acetylase) activity that has the additional advantage of
being nonradioactive.Materials and methods
Chemicals
The ﬂuorescent substrate MAL (1) was synthesized
from a-BOC-e-acetyl lysine (Calbiochem) and 7-amino-
4-methylcoumarin (Sigma) as outlined elsewhere [14,17].
Recently, it has also become commercially available
(Calbiochem; No. 382155). Trichostatin A (TSA) (3)
was purchased from Sigma. SW55 (4) was synthesized as
described in the literature [18]. The sirtuin inhibitor
sirtinol (5) was purchased from Alexis.
Synthesis
(S)-[5-Acetylamino-1-(4-methyl-2-oxo-2H-chromen-
7-ylcarbamoyl)-pentyl]-carbamic acid benzyl ester (2),
also termed Z-MAL, was synthesized from N-a-benzyl-
oxycarbonyl-N-e-acetyl-lysine (0.39g, 1.21mmol; prepared
according to the literature [19]), 7-amino-4-methyl-
coumarin (0.21 g, 1.21mmol), and POCl3 (0.25mL).N-a-
Benzyloxycarbonyl-N-e-acetyl-lysine and equivalent
amounts of 7-amino-4-methylcoumarin were dissolved in
dry pyridine (7mL) at )15 C. Phosphoryl chloride
(0.25mL) was then added dropwise via a syringe with
vigorous stirring, resulting in an orange-red solution.
After stirring for 1 h at )15 C, the mixture was then
poured into the 10-fold volume of ice/H2O and extracted
three times with 50mL of ethyl acetate. The combined
organic phase was washed consecutively with H2O, 2M
HCl, H2O, 5% NaHCO3, H2O, and saturated brine
(50mL each). The organic layer was dried over Na2SO4
and the solvent was evaporated. The resulting product
was chromatographedwith ethyl acetate/methanol (20:1).
Yield: 0.25 g (43%), mp 158 C. IR: 3311, 2939, 2862,
1684, 1621, 1524. 1H-NMR (DMSO-d6): d 10.49 (s, 1H),
7.81 (t, 1H, 3J ¼ 5:47Hz), 7.75 (d, 1H, 4J ¼ 1:75Hz), 7.70
(d, 1H, 3J ¼ 8:60 Hz), 7.65 (d, 1H, 3J ¼ 7:62), 7.47 (dd,
3J ¼ 8:79 Hz, 4J ¼ 1:96 Hz), 7.32 (s, 5H), 6.25 (s, 1H),
5.01 (s, 2H), 4.12–4.09 (m, 1H), 2.99–2.96 (m, 2H), 2.38 (s,
3H), 1.75 (s, 3H), 1.68–1.27 (m, 6H). 13C-NMR (DMSO-
d6): d 171.68, 168.59, 159.74, 155.89, 153.36, 152.84,141.98, 136.70, 128.14 (2 C), 127.62, 127.55 (2 C), 125.75,
115.05, 114.88 112.13, 105.06, 65.43, 55.54, 38.27, 31.32,
28.88, 23.17, 22.65, 18.05.MS (EI):m=z 371 (55), 271 (70).
Anal. (C26H29N3O6) C, H, N.
Apparatus
A Shimadzu RF 535 was used as ﬂuorescence detec-
tor for HPLC. A Lichrosorb RP 18–5 lm (125 3mm;
Knauer) column with a guard column of the same ma-
terial (5 3mm; Knauer) and a Luna 5 lm Phenyl-
Hexyl (250 4mm; Phenomenex) column were used for
the HPLC analysis of the incubation mixture and the
extracted substrate solutions. A BMG Polarstar plate
reader was used to quantify the ﬂuorescence in the ho-
mogeneous assay. Black BMG micoplates were used for
the plate reader based assays.
Enzymes
Rat liver HDAC was puriﬁed with ammonium sulfate
precipitation and chromatography on Q-Sepharose with
an increasing gradient of sodium chloride according
to published procedures [15,20]. Such preparations
are commercially available (Calbiochem, Alexis) but
some contain tris-buﬀer which is not compatible with
homogenous assay. As the puriﬁed rat liver preparation
does not contain sirtuin activity (data not shown), a
crude extract was used for the sirtuin assay. For this
preparation, 15 g of rat liver was cut into small pieces
and homogenized in 70mL of lysis buﬀer (42mM
Na2HPO4, 8mM NaH2PO4, pH 7.5, 0.25mM sucrose,
25mM KCl, 5mM MgCl2, 2mM dithiothreitol, and
Complete protease inhibitors (Roche)) and centrifuged
at 20,000g. The supernatant was used as a source for
sirtuin deacetylase activity.
HeLa nuclear extract was purchased from Geneka
(200 lg/40 lL; catalogue No. 100200) and from Upstate
(50 lg/25 lL; catalogue No. 12-309). The recombinant
sirtuin hSIRT1 was purchased from Biomol (3.5U/lL;
catalogue No. SE-239).
Recombinant HDAC1 [11] and HDAC6 [21] were
prepared as full-length FLAG-tagged proteins as out-
lined elsewhere [22,23].
Reactivity assay with rat liver enzyme
For the reactivity with the HPLC assay [24] com-
pounds 1 and 2 were used as substrates and an internal
standard, 7-hydroxycoumarin, was always included for
quantitation purposes. The HPLC assay was performed
on the Lichrosorb column with acetonitrile/water (40/60
v/v) as mobile phase at a ﬂow rate of 0.6mL/min. Ex-
citation wavelength was 330 nm and emission wave-
length 390 nm. Retention times were 3.65min (1),
5.40min (2), and 2.15min (7-hydroxycoumarin). Results
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determine the resulting metabolites, we used a Luna 5-
lm Phenyl-Hexyl column with acetonitrile/water/triﬂu-
oroacetic acid (55/45/0.01 v/v/v) as mobile phase at a
ﬂow rate of 0.5mL/min. Retention times were 8.24min
for 1, 4.01min for the metabolite of 1, 9.66min for 2,
3.99min for the metabolite of 2, and 7.66min for 7-
hydroxycoumarin. Stock solutions of compounds 1 and
2 were made at 12.6mM in DMSO and were further
diluted with enzyme buﬀer (1.4mM NaH2PO4;18.6mM
Na2HPO4, pH 7.9, 0.25mM EDTA, 10mM NaCl, 10%
(v/v) glycerol, 10mM 2-mercaptoethanol). A stock so-
lution was prepared using an aliquot of 10 lL of the
substrate (1 or 2), 15 lL of a solution of the standard 7-
hydroxycoumarin in DMSO (6.3mg/mL), and enzyme
buﬀer to a total volume of 1mL. A 10-lL amount of the
substrate/standard stock solution was added to a mix-
ture of 100 lL of rat enzyme preparation (at 4 C) and
10 lL of buﬀer. After 15min at 4 C, the mixture was
then incubated at 37 C for the desired length of time.
After this time, the reaction was stopped by the addition
of 72 lL of 1M HCl/0.4 M sodium acetate and 800 lL
ethyl acetate. After it was centrifuged (10,000 rpm,
5min), an aliquot of 200 lL of the upper phase was
taken and the solvent removed by a stream of nitrogen.
The residue was dissolved in 600 lL of chromatography
eluent, and 20 lL was injected via autosampler onto the
HPLC system. The amount of remaining substrate is
calculated relative to the substrate control without en-
zyme (each as quotient of the peak area of the substrate
divided by the peak area of the internal standard). For
the determination of the metabolites, the incubation was
stopped by addition of 1000 lL of acetonitrile instead of
72 lL of 1M HCl/0.4M sodium acetate. The mixture
was then centrifuged (10,000 rpm, 5min) and the su-
pernatant was taken oﬀ the enzyme pellet and 20 lL
were injected via autosampler into the HPLC system.
Reactivity assay with HeLa nuclear extract
The same procedure as above was run using com-
mercial HeLa nuclear extracts instead of rat liver en-
zyme preparation. The extracts were diluted with
enzyme buﬀer (1:10). Instead of 100 lL enzyme prepa-
ration, 45 lL (Geneka) or 60 lL (Upstate) of the dilu-
tion were taken; 5 lL of buﬀer or inhibitor solution and
10 lL of substrate/standard solution were added. The
mixture was incubated for 15min at 4 C and then for
3 h (Geneka) or 90min (Upstate) at 37 C and consec-
utively treated as described above.
Reactivity assay with a sirtuin
For the determination of the reactivity with hSIRT1,
a diﬀerent enzyme buﬀer (25mM Tris–HCl, pH 8.0,
137mM NaCl, 2.7mM KCl, 1mMMgCl2) was used forall dilutions and incubations. The substrate solutions
were prepared as described above. A NADþ stock so-
lution was prepared in water (6mM); 5 lL of the sub-
strate stock solution was mixed with 2, 2.5, or 5 lL of
hSIRT1, 5 lL of the NADþ solution, and enzyme in-
cubation buﬀer to a total volume of 60 lL. The incu-
bation at 37 C was stopped after 4 or 8 h by the
addition of 36 lL of 1M HCl/0.4M sodium acetate,
extracted with 400 lL of ethyl acetate, and consecutively
treated as mentioned above. For the determination of
the IC50 of sirtinol (5), inhibitor solutions of 60, 20, 6, 2,
and 0.6mM were prepared in DMSO; 5 lL of the sub-
strate/internal standard stock solution was added to a
mixture of 2.5 lL of hSIRT1, 5 lL of the NADþ stock
solution, 1 lL of each inhibitor solution, and 46.5 lL of
the enzyme incubation buﬀer. This mixture was incu-
bated for 16 h at 37 C. The reaction was stopped and
analyzed as described above.
For the sirtuin assay with the crude rat liver prepa-
ration, 5 lL of the stock solution of NADþ (24mM in
water) or 5 lL of buﬀer and 10 lL of a stock solution of
SW55 (4) (240 lM in buﬀer) were mixed with 90 lL of
the enzyme preparation. For the inhibitor testing, a
stock solution of sirtinol was prepared in DMSO
(24mM); 5 lL of the inhibitor solution or 5 lL of
DMSO as vehicle were added to the enzyme. The reac-
tion was started by the addition of 10 lL of the
stock solution of substrate/internal standard. The incu-
bation at 37 C was stopped after 2, 4, or 16 h by the
addition of 72 lL of 1M HCl/0.4M sodium acetate. The
mixture was then extracted with 800 lL of ethyl
acetate and analyzed on the HPLC system as described
above.
Homogeneous HDAC activity assay
For the homogeneous assay [15], stock solutions of 1
and 2 of 12.6mM in DMSO were prepared. Aliquots of
10 lL of these solutions were diluted in enzyme buﬀer
(1.4mM NaH2PO4, 18.6mM Na2HPO4, pH 7.9,
0.25mM EDTA, 10mM NaCl, 10% (v/v) glycerol,
10mM 2-mercaptoethanol) to a total volume of 1mL
and used as substrate solutions. For inhibitor testing,
the stock solution of TSA (3, 3.3mM in DMSO) was
diluted to 3.3, 1.1, 0.33, 0.11, and 0.033 lM in enzyme
buﬀer; 50 lL of the rat liver enzyme was mixed with
10 lL of the buﬀer as blank, with 5 lL of the substrate
solution and 5 lL of the buﬀer as negative control and
with 5 lL of the substrate solution and 5 lL of the po-
sitive control solution (3.3 lM TSA) as a positive con-
trol. Samples were prepared by mixing 50 lL of the
enzyme solution with 5 lL of each inhibitor solution and
5 lL of the substrate solution. These mixtures were then
incubated for 90min at 37 C and the reaction was
stopped by the addition of 190 lL of a mixture of TSA
solution (3.3 lM in enzyme buﬀer), borate buﬀer
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9.5), and a solution of naphthalene-2,3-dicarboxalde-
hyde (16mM in methanol) in a ratio of 5/180/5 (v/v/v).
The ﬂuorescence was measured at 330/390 nm. The
amount of remaining substrate in the positive control
with TSA is calculated relative to the negative control
without inhibitor to give the 100% value. Partial con-
version is related to that value.Reactivity assay with the FLAG-HDAC1 and FLAG-
HDAC6
The immunoprecipitation of the enzymes from the
cell lysates was performed as described elsewhere [22].
M2 agarose (Sigma) was used at 25 lL/mL lysate. The
immunoprecipitated enzymes were washed in enzyme
buﬀer and used as enzyme source in the homogeneous
assay; 2.5 lL of the agarose beads were resuspended in
52.5 lL and mixed with 5 lL of the buﬀer as blank and
with 5 lL of the substrate solution for the reactivity
assay. As a control, 55 lL of enzyme buﬀer was mixed
with 5 lL of the substrate solution. These mixtures were
then incubated for 3 h at 37 C. The reaction was stop-
ped and analyzed as described above. The amount of
remaining substrate in the enzyme-containing samples
was calculated relative to the amount of substrate in the
control samples.Fig. 2. Time-dependent reaction of 1 (j) and 2 (N) with rat liver
enzyme (n ¼ 2, SD).Results
The ﬂuorescent substrate MAL (1) is readily deacet-
ylated by rat liver but not so well by HeLa nuclear ex-
tract histone deacetylases. The benzyloxycarbonyl (Z)
modiﬁcation Z-MAL (2) (see Fig. 1) was also shown to
be accepted as a substrate for histone deacetylases. We
incubated both substrates with rat liver enzyme prepa-
ration as a source of histone deacetylases of classes I and
II (immunoblotting data not shown) and were able to
observe a time-dependent conversion of both substrates.
The Z analogue of MAL is more quickly deacetylated
than MAL (see Fig. 2). After 1 h of incubation at 37 C,
more than 65% of Z-MAL but only 38% of MAL is
deacetylated. To test whether Z-MAL is able to replace
MAL in the homogeneous assay, we measured the IC50Fig. 1. Deacetylation of MAL (1) and Zvalue of trichostatin A (3, see Fig. 3) using the homo-
geneous histone deacetylase assay HDASH [15] with 1
and 2 as substrates (see Fig. 4). The IC50 was
6.04 0.67 nM for 1 as substrate and 10.1 1.5 nM for
2 as substrate. We then investigated whether the newly
discovered HDAC substrate 2 can be used in assaying
human histone deacetylase activity which converted
MAL rather slowly. HeLa nuclear extract serves as a
source for diﬀerent histone deacetylases of classes I and
II (immunoblotting data not shown). We were able to
observe a signiﬁcant diﬀerence in conversion (see Fig. 5)
with 2 being deacetylated in both instances to a much
larger extent in the same time frame. We then wanted to
analyze the reactivity of the substrates toward puriﬁed
HDAC subtypes. We prepared FLAG-tagged HDAC1
as a member of class I [11] and FLAG-tagged HDAC6
as a class II enzyme (subclass IIb) [21]. As shown in Fig.
6, 2 is converted to a larger extent by HDAC1 than is 1
in the same time frame. For HDAC6, the diﬀerence
between the conversion rates of 1 and 2 is not statisti-
cally signiﬁcant.
So far no experiments with nonpeptidic substrates
have been performed with class III histone deacetylases
(sirtuins). After incubation of 1 and 2 for 8 h at 37 C
with 17.5 U of hSIRT1 as a recombinant member of
the sirtuins, we observed a deacetylation of about 90%
of 2 but only about 50% of 1 (see Fig. 7A). With only
7 U of the enzyme and 4 h at 37 C, we still see a
signiﬁcant conversion of 2 but not of 1. To check-MAL (2) by histone deacetylases.
Fig. 3. Speciﬁc inhibitors of diﬀerent histone deacetylases.
Fig. 4. IC50 determination of trichostatin A with 1 (j) and 2 (N) in the
homogeneous assay (n ¼ 2, SD). The rates of conversion without
inhibitor were 54% for 1 and 77% for 2.
Fig. 5. Conversion of 1 (open bars) and 2 (ﬁlled bars) with HeLa
nuclear extract (n ¼ 2 or 3, SD).
Fig. 6. Conversion of 1 (open bars) and 2 (ﬁlled bars) with re-
combinant histone deacetylases (n ¼ 3–6, SD).
2 Footnote added in proof: We have recently observed that E. coli
expressed recombinant Sirt2 appears to precipitate in vitro in the
presence of sirtinol. Some of this precipitation might have contributed
to the inhibition of the enzyme by sirtinol observed in vitro.
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sirtuins and not by a contamination with histone de-
acetylases of classes I or II, we added 5 lM of the class
I and II speciﬁc inhibitor trichostatin A (3). We could
not detect any inhibition of the deacetylation of 2 (data
not shown). We then determined the IC50 of the spe-
ciﬁc sirtuin inhibitor sirtinol (5) (see Fig. 3) [25] with
hSIRT1 and were able to observe an IC50 value of
60 lM, which is comparable to reported data in the
literature (reported IC50 values of 68 lM for the re-combinant yeast sir2p and of 38 lM for the re-
combinant human hGST-SIRT2) [25] (see Fig. 7B).2
For the unspeciﬁc sirtuin inhibitor nicotinamide [26],
we were able to observe an inhibition of the conversion
of 2 at 30 lM (21% inhibition) and 100 lM (44% in-
hibition) (data not shown). We were not able to detect
sirtuin activity in our chromatographically puriﬁed rat
liver enzyme (data not shown). Therefore, we used a
crude extract from rat liver and were able to detect
NADþ-dependent deacetylase activity (see Fig. 8). The
histone deacetylases of classes I and II have to be in-
hibited in that crude extract to detect the sirtuin ac-
tivity. To accomplish this task, we used the speciﬁc
inhibitor of classes I and II, SW55 (4) [18] (see Fig. 3).
The NADþ-dependent deacetylase activity from this
source can be inhibited by sirtinol (5). The high vari-
ability of the data can be explained with the very in-
soluble sirtinol, which precipitates easily in buﬀer- and
protein-containing solutions and with the crude enzyme
preparation.
Fig. 7. (A) Conversion of 1 (open bars) and 2 (ﬁlled bars) with recombinant hSIRT1 (n ¼ 2, SD). (B) IC50 determination of sirtinol with 2 and
hSIRT1 (n ¼ 2, SD). The rate of conversion without inhibitor was 44%.
Fig. 8. Conversion of 2 with crude rat liver preparation under speciﬁc
inhibition of classes I and II HDAC (all samples contain 20lM of the
class I and II inhibitor SW55) with and without NADþ and with and
without the speciﬁc sirtuin inhibitor sirtinol (n ¼ 2, SD). Diﬀerences
between 4 h )NAD and 4h +NAD+ inhibitor sirtinol are not signiﬁ-
cant.
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The new ﬂuorescent histone deacetylase substrate
Z-MAL can be considered a valuable improvement of
the established ﬂuorescent substrate MAL. We were
able to show that Z-MAL is accepted by histone
deacetylases of all human classes known so far. The
deacetylation of Z-MAL by mixtures of various classes
of deacetylases and by examples of puriﬁed recombinantsubtypes from all three classes is more rapid and, with
the exception of FLAG-HDAC6, occurs to a larger
extent than the deacetylation of MAL. Thus, it has a
broader range of application and shows a greater sen-
sitivity toward samples with low enzymatic activity. On
the other hand, the observed class preference of MAL
indicates that it may serve as a starting point for the
development of subtype-selective small-molecule sub-
strates. The conversion of Z-MAL to its metabolite can
be inhibited by speciﬁc inhibitors with concentrations in
the same range as the published data. This substrate Z-
MAL may be valuable for rapid nonisotopic screening
of HDAC activity and its inhibition. It can replace
MAL in the homogeneous histone deacetylase assay
that was published by our group previously and should
lead to decreased assay time in high-throughput
screening. Especially valuable is the conversion of this
new substrate by human and rat liver NADþ-dependent
class III histone deacetylases (sirtuins) that show a
mechanism of catalysis completely diﬀerent from those
of classes I and II. Existing deacetylation assays rely on
the determination of released acetate, which despite its
usage is not very suitable for the sirtuins. As the cleaved
acetyl group is transferred and O-acetyl-ADP-ribose is
formed only part of the radioactivity will be liberated as
[3H]acetic acid that is extracted and counted in the
standard protocols. This is the ﬁrst report of a non-
peptidic substrate for this enzyme class which can be
quantitated directly and should be very valuable in the
search for new inhibitors and in the elucidation of the
cellular functions of this poorly understood class of
deacetylases. The proof of principle that NADþ-de-
pendent class histone deacetylase activity can be selec-
tively detected and inhibited in readily available extracts
that contain class I and II deacetylases is a very valuable
extension of the scope of potential applications.
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